

**FOR IMMEDIATE RELEASE**  
**November 28, 2006**  
**Contact: Daryl Risinger**  
**805.562.0511**

**Research on Nocturnal Titration of POC Published**  
Additional research supports the use of the Inogen One as a  
continuous duty oxygen system

SANTA BARBARA, CA - As the adoption of portable oxygen concentrators (POCs) continues to increase, questions regarding implementation and titration are being addressed by one manufacturer. Inogen recently completed a study on nocturnal titration strategies for the Inogen One Oxygen System. The November 2006 issue of the science journal *Respiratory Care* includes the study lead by well known homecare clinician James Stegmaier, RRT-NPS, CCM entitled "Determination of an Appropriate Nocturnal Setting for a Portable Oxygen Concentrator with Pulsed Dosed Oxygen Delivery." This study marks the fourth scientific paper showing favorable results for the Inogen One and the second study validating its clinical application during sleep.

The purpose of the Stegmaier study was to determine if a single oxygen setting titration on the Inogen One during ambulation and routine activities of daily living would provide for appropriate oxygen setting for use during sleep. Stegmaier concluded that the selection of the pulse-dosed oxygen setting on the Inogen One based on daytime titration produces clinically effective nocturnal oxygen therapy as was evidenced by a mean oxygen saturation of 92% and no clinically relevant desaturations in any of the study participants.

"Inogen is committed to producing clinically efficacious oxygen technologies and we encourage objective, peer-reviewed research that helps validate what is now proven technology" commented Kathy Odell, Inogen CEO. "Since our inception, Inogen has sought strong scientific and clinical validation as part of the development process and we are pleased to see growing efforts in this area by researchers like Stegmaier and his contemporaries" added Odell.

"Until recently, much of the limited published work in the area of home medical equipment has been bench work that

focused on validating device specifications and noting the technical differences in various devices" noted Joseph Lewarski, BS, RRT, FAARC, Inogen Vice President of Clinical Affairs. "While bench testing is interesting and important work, the real measure of device performance is its impact on patient care and clinical outcomes" added Lewarski.

The Stegmaier study represents the fourth published study within the past two years by Inogen. Other research has focused on nocturnal efficacy of the Inogen One compared to continuous flow, use in high-flow oxygen patients, and independent power needs of the ambulatory oxygen patient.

*Inogen is innovation in oxygen therapy. With a team of known leaders in the provider industry, deep experience in medical devices, talented engineers and associates each committed to revolutionizing oxygen therapy, our vision is to develop innovative, cost effective respiratory home healthcare equipment that improves quality of life for patients and bottom line profits for providers. And we are proud to introduce our first commitment to that vision: The Inogen One.*

*One Solution: The single solution for home and away, for today and tomorrow, for patients and provider.*

[www.inogen.net](http://www.inogen.net)

-##-